Triazolam
- Triazolam TRIAZOLAM .25 mg/1 Hikma Pharmaceuticals USA Inc.
- Triazolam TRIAZOLAM .25 mg/1 A-S Medication Solutions
- Triazolam TRIAZOLAM .25 mg/1 Zydus Pharmaceuticals USA Inc.
- Triazolam TRIAZOLAM .25 mg/1 PD-Rx Pharmaceuticals, Inc.
- Triazolam TRIAZOLAM .25 mg/1 Ingenus Pharmaceuticals, LLC
- Halcion TRIAZOLAM .25 mg/1 Pharmacia & Upjohn Company LLC
- Triazolam TRIAZOLAM .25 mg/1 PD-Rx Pharmaceuticals, Inc.
- Triazolam TRIAZOLAM .25 mg/1 Zydus Lifesciences Limited
- Triazolam TRIAZOLAM .25 mg/1 Bryant Ranch Prepack
- Halcion TRIAZOLAM .25 mg/1 Pharmacia & Upjohn Company LLC
- Triazolam TRIAZOLAM .25 mg/1 Greenstone LLC
- Triazolam TRIAZOLAM .25 mg/1 Greenstone LLC
- Triazolam TRIAZOLAM .25 mg/1 A-S Medication Solutions
- Triazolam TRIAZOLAM .25 mg/1 Greenstone LLC
Summary of product characteristics
Effective Time
20230928
Version
2
Spl Product Data Elements
Triazolam Triazolam TRIAZOLAM TRIAZOLAM D&C RED NO. 27 FD&C BLUE NO. 1 LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE SILICON DIOXIDE SODIUM LAURYL SULFATE STARCH, CORN light-grayish blue elliptical 12;89 Triazolam Triazolam TRIAZOLAM TRIAZOLAM LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE POVIDONE SILICON DIOXIDE SODIUM LAURYL SULFATE STARCH, CORN off-white elliptical 1521
Application Number
ANDA213003
Brand Name
Triazolam
Generic Name
Triazolam
Product Ndc
70771-1162
Product Type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Package Label Principal Display Panel
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1576-8 Triazolam Tablets USP, 0.125 mg 10 Tablets Rx only NDC 70771-1162- 8 Triazolam Tablets USP, 0.25 mg 10 Tablets Rx only 0.125 mg label 0.25 mg label
Spl Medguide
SPL MEDGUIDE
Drug section
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.